MicroRNAs As Oncogenes or Tumour Suppressors in Oesophageal Cancer: Potential Biomarkers and Therapeutic Targets

Overview

Journal Cell Prolif

Date 2014 Jun 10

PMID 24909356

Citations 56

Authors

J Huang

S-Y Zhang

Y-M Gao

Y-F Liu

Y-B Liu

Z-G Zhao

K Yang

Affiliations

Soon will be listed here.

Abstract

MicroRNAs are a class of small, non-coding RNAs that can negatively regulate protein-coding genes, and are associated with almost all known physiological and pathological processes, especially cancer. The number of studies documenting miRNA expression patterns in malignancy continues to expand rapidly, with continuously gained critical information regarding how aberrantly expressed miRNAs may contribute to carcinogenesis. miRNAs can influence cancer pathogenesis, playing a potential role as either oncogenes or tumour suppressors. Recently, several miRNAs have been reported to exert different regulatory functions in oesophageal cancer - the carcinoma typically arising from the epithelial lining of the oesophagus. These miRNAs also have potential clinical applications towards developing biomarkers or targets for possible use in diagnosis or therapy in oesophageal cancer. In this review, we have summarized the two (oncogenic or tumour suppressive) roles of miRNAs here, and their applications as potential biomarkers or therapeutic targets, which may illuminate future treatment for oesophageal cancer.

Citing Articles

PAQR4 oncogene: a novel target for cancer therapy.

Patil D, Raut S, Joshi M, Bhatt P, Bhatt L Med Oncol. 2024; 41(6):161.

PMID: 38767705 DOI: 10.1007/s12032-024-02382-w.

The Role of Autophagy in Human Uveal Melanoma and the Development of Potential Disease Biomarkers and Novel Therapeutic Paradigms.

Wang J, Paulus P, Niu Y, Zhu L, Morisseau C, Rawling T Biomedicines. 2024; 12(2.

PMID: 38398064 PMC: 10886749. DOI: 10.3390/biomedicines12020462.

Molecular Biology and Clinical Management of Esophageal Adenocarcinoma.

Li S, Hoefnagel S, Krishnadath K Cancers (Basel). 2023; 15(22).

PMID: 38001670 PMC: 10670638. DOI: 10.3390/cancers15225410.

LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis.

Hu J, Huang H, Xi Z, Ma S, Ming J, Dong F Cell Death Dis. 2022; 13(9):800.

PMID: 36123344 PMC: 9485163. DOI: 10.1038/s41419-022-05189-7.

Targeting Autophagy for Developing New Therapeutic Strategy in Intervertebral Disc Degeneration.

Bahar M, Hwang J, Ahmed M, Lai T, Pham T, Elashkar O Antioxidants (Basel). 2022; 11(8).

PMID: 36009290 PMC: 9405341. DOI: 10.3390/antiox11081571.

References

Sun J, Chen Z, Tan X, Zhou F, Tan F, Gao Y . MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med Oncol. 2013; 30(1):411. DOI: 10.1007/s12032-012-0411-9. View

Zhang H, Zhang K, Liao L, Li L, Du Z, Wu B . miR-200b suppresses invasiveness and modulates the cytoskeletal and adhesive machinery in esophageal squamous cell carcinoma cells via targeting Kindlin-2. Carcinogenesis. 2013; 35(2):292-301. DOI: 10.1093/carcin/bgt320. View

Gu J, Wang Y, Wu X . MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. 2012; 19(7):1292-300. DOI: 10.2174/138161213804805775. View

Trivers K, Sabatino S, Stewart S . Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer. 2008; 123(6):1422-8. DOI: 10.1002/ijc.23691. View

Bansal A, Lee I, Hong X, Anand V, Mathur S, Gaddam S . Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol. 2011; 106(6):1055-63. DOI: 10.1038/ajg.2011.37. View

Borchert G, Lanier W, Davidson B . RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006; 13(12):1097-101. DOI: 10.1038/nsmb1167. View

Yu H, Duan B, Jiang L, Lin M, Sheng H, Huang J . Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy. Am J Transl Res. 2013; 6(1):71-7. PMC: 3853426. View

Weng W, Wu Q, Yu Y, Mei W, Wang X . A novel chemotherapeutic arene ruthenium(II) drug Rawq01 altered the effect of microRNA-21 on PTEN/AKT signaling pathway in esophageal cancer cells. Anticancer Res. 2013; 33(12):5407-14. View

Ni Y, Meng L, Wang L, Dong W, Shen H, Wang G . MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene. 2013; 517(2):197-204. DOI: 10.1016/j.gene.2012.12.031. View

10.

Hu Y, Correa A, Hoque A, Guan B, Ye F, Huang J . Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2010; 128(1):132-43. PMC: 2937084. DOI: 10.1002/ijc.25330. View

11.

Tran N, Hutvagner G . Biogenesis and the regulation of the maturation of miRNAs. Essays Biochem. 2013; 54:17-28. DOI: 10.1042/bse0540017. View

12.

Nelson P, Baldwin D, Marie Scearce L, Oberholtzer J, Tobias J, Mourelatos Z . Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods. 2005; 1(2):155-61. DOI: 10.1038/nmeth717. View

13.

Suzuki S, Yokobori T, Tanaka N, Sakai M, Sano A, Inose T . CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep. 2012; 28(2):465-72. DOI: 10.3892/or.2012.1831. View

14.

Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T . Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol. 2009; 42(2):102-9. DOI: 10.1007/s00795-009-0443-1. View

15.

Wang K, Li J, Guo H, Xu X, Xiong G, Guan X . MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis. 2012; 33(11):2147-54. DOI: 10.1093/carcin/bgs259. View

16.

Li J, Wang K, Chen X, Meng H, Song M, Wang Y . Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol Biol. 2012; 13:4. PMC: 3311059. DOI: 10.1186/1471-2199-13-4. View

17.

Wang Y, Li M, Zang W, Ma Y, Wang N, Li P . MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell Oncol (Dordr). 2013; 36(5):385-94. DOI: 10.1007/s13402-013-0144-6. View

18.

Fassan M, Volinia S, Palatini J, Pizzi M, Baffa R, de Bernard M . MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer. 2010; 129(7):1661-70. PMC: 4303574. DOI: 10.1002/ijc.25823. View

19.

Nana-Sinkam S, Croce C . Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2012; 93(1):98-104. DOI: 10.1038/clpt.2012.192. View

20.

Wu X, Ajani J, Gu J, Chang D, Tan W, Hildebrandt M . MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013; 6(3):196-205. PMC: 3608471. DOI: 10.1158/1940-6207.CAPR-12-0276. View